MiNK Therapeutics (INKT) AI Stock Analysis

• Market Cap: $51.40M
• Dividend Yield: N/A
• Average Volume (3M): 39.56K
• Price to Earnings (P/E): ―
• Beta (1Y): >-0.01
• Revenue Growth: N/A
• EPS Growth: 21.48%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.65
• Shares Outstanding: 4,694,155
• 10 Day Avg. Volume: 31,712
• 30 Day Avg. Volume: 39,559
• PEG Ratio: 0.04
• Price to Book (P/B): -1.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.73
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -217.43
• Enterprise Value/Ebitda: -3.52
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -3.61
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $12.50 ▲(11.71% Upside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is primarily held down by weak financial fundamentals (pre-revenue, negative equity, and highly concerning TTM cash flow metrics). This is partially offset by a constructive earnings call centered on clinical progress and runway, while technicals and valuation provide limited additional support.

Positive Factors

Clinical efficacy of AGENT-797

Durable median overall survival (~23 months) and observed complete remissions in heavily pretreated patients provide lasting validation of the iNKT platform's potency across tumor types, improving the program's regulatory and partner-attraction prospects and reducing long-term clinical risk.

Strategic partnerships and grants

Public-private grants and academic partnerships deliver non-dilutive capital, clinical trial support, and external validation. These relationships strengthen development resources, expand trial networks, and materially lower execution risk versus relying solely on capital markets over the next 2–6 months and beyond.

Scalable manufacturing capability

Ability to produce billions of iNKT cells per donor supports the allogeneic, off-the-shelf model's scalability and unit economics. Robust manufacturing capacity is a durable competitive advantage that de-risks supply constraints and readies programs for larger trials and eventual commercialization.

Negative Factors

Negative stockholders' equity

Persistent negative equity reflects accumulated losses and limits borrowing capacity, weakening financial flexibility. This structural balance-sheet weakness increases the likelihood of dilutive financings and constrains strategic options until profitability or a recapitalization restores equity.

Extremely negative TTM operating cash flow

An extraordinarily negative TTM operating cash flow indicates unsustainable cash burn relative to the company's size and resources. Over the medium term this creates acute dependence on external financing, heightening execution and dilution risk and threatening continuous program funding.

Pre-revenue with persistent operating losses

Having no product revenue and ongoing net losses means the company must finance R&D and trials externally until commercialization. This structural reliance on fundraising increases uncertainty around long-term profitability and heightens the risk of program delays or scope reductions.

MiNK Therapeutics Business Overview & Revenue Model

Company Description

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

How the Company Makes Money

MiNK Therapeutics makes money through the research and development of its iNKT cell therapies, which are primarily funded through a combination of private investments, public offerings, and strategic partnerships. The company generates revenue by entering into collaboration agreements with larger pharmaceutical companies who are interested in its proprietary technology platform. These partnerships may include upfront payments, milestone payments based on developmental progress, and royalties on future sales if the therapies are successfully commercialized. Additionally, MiNK might receive grants or other funding from governmental and non-governmental organizations to support its research initiatives.

MiNK Therapeutics Financial Statement Overview

Summary

Early-stage, pre-revenue profile with ongoing losses and negative equity. While annual net loss and 2024 operating cash flow improved versus prior years, the TTM operating and free cash flow figures are extremely negative and raise significant funding/financial stability risk.

Income Statement

MiNK Therapeutics is still pre-revenue (revenue is $0 in both TTM (Trailing-Twelve-Months) and recent annual periods), with persistent operating losses. Losses have narrowed versus 2022–2023 (annual net loss improved from about -$28.0M in 2022 and -$22.5M in 2023 to about -$10.8M in 2024), but TTM (Trailing-Twelve-Months) net loss remains sizable at roughly -$12.4M. Reported margin figures are not very informative given the absence of revenue, and gross profit is negative across periods, underscoring ongoing R&D/operating spend without commercialization yet.

Balance Sheet

The balance sheet shows elevated financial risk: stockholders’ equity is negative in TTM (Trailing-Twelve-Months) (about -$13.5M) and also negative in 2024 (about -$19.6M), which limits financial flexibility. Debt is present (about $5.7M in TTM (Trailing-Twelve-Months) and $4.9M in 2024); leverage ratios are difficult to interpret when equity is negative, but the setup still implies a thinner capital cushion. A positive is that total assets increased meaningfully in TTM (Trailing-Twelve-Months) (~$15.0M) versus 2024 (~$5.7M), suggesting improved resources on the balance sheet, though profitability has not followed.

Cash Flow

Cash generation remains weak, with operating cash flow consistently negative. 2024 operating cash flow was about -$9.6M (an improvement versus -$15.8M in 2023 and -$18.9M in 2022), but TTM (Trailing-Twelve-Months) operating cash flow is extraordinarily negative (about -$1.35B) and free cash flow is similarly negative, which is a major red flag versus the company’s income loss levels and historical pattern. Free cash flow has been volatile (positive growth in 2023–2024 but declines in 2021–2022), and overall the business appears dependent on external funding until revenue ramps.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-197.05K	-215.44K	-204.62K	-121.75K	-77.96K	-55.06K
EBITDA	-12.16M	-10.57M	-22.25M	-27.87M	-27.70M	-13.74M
Net Income	-12.36M	-10.78M	-22.46M	-27.99M	-30.21M	-16.24M
Balance Sheet
Total Assets	14.96M	5.72M	4.55M	21.47M	40.24M	4.56M
Cash, Cash Equivalents and Short-Term Investments	14.28M	4.58M	3.37M	19.64M	38.89M	2.69M
Total Debt	5.73M	4.92M	0.00	0.00	0.00	43.82M
Total Liabilities	28.48M	25.31M	22.61M	21.87M	16.47M	58.43M
Stockholders Equity	-13.51M	-19.59M	-18.06M	-401.30K	23.78M	-53.87M
Cash Flow
Free Cash Flow	-1.35B	-9.56M	-15.84M	-19.12M	-13.08M	-8.43M
Operating Cash Flow	-1.35B	-9.56M	-15.76M	-18.87M	-12.83M	-8.34M
Investing Cash Flow	0.00	0.00	-73.56K	-250.05K	-248.98K	-95.21K
Financing Cash Flow	14.12M	10.82M	-407.17K	-155.60K	49.26M	11.11M

MiNK Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INKT, the sentiment is Negative. The current price of 11.19 is below the 20-day moving average (MA) of 11.22, below the 50-day MA of 11.69, and below the 200-day MA of 12.74, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 40.69 is Neutral, neither overbought nor oversold. The STOCH value of 35.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INKT.

MiNK Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ORMP	62 Neutral	$135.93M	3.41	24.38%	―	―	814.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INKT	48 Neutral	$51.40M	-3.61	―	―	―	21.48%
VERU	46 Neutral	$41.41M	-2.13	-60.25%	―	-100.00%	55.10%
ARMP	46 Neutral	$391.74M	-8.13	―	―	-7.55%	-13.09%
QNCX	40 Underperform	$7.00M	―	-247.78%	―	―	2.26%

MiNK Therapeutics Corporate Events

MiNK Therapeutics announces board resignation amid public appointment

On December 29, 2025, Robert Kadlec, MD, resigned from the Board of Directors of MiNK Therapeutics, Inc., including all committee roles, following his acceptance of a senior public service appointment as Assistant Secretary of War for Nuclear Deterrence and Chemical and Biological Defense Policy and Programs in the U.S. government. Dr. Kadlec, who joined the board in October 2024, had provided the company with strategic insights drawn from his extensive background in medicine, public health preparedness, and national service, and his departure reflects both the prestige of his new role and MiNK’s connections to high-level expertise, with the company publicly thanking him for his contributions and service during his tenure.

The most recent analyst rating on (INKT) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on MiNK Therapeutics stock, see the INKT Stock Forecast page.